ライフサイエンスコーパス: arthritis

1 o the cellular immune landscape of psoriatic arthritis.

2 ctive inhibition of IL-23 to treat psoriatic arthritis.

3 transition from autoimmunity to inflammatory arthritis.

4 and IL17F, in patients with active psoriatic arthritis.

5 stinct way to control joint inflammation and arthritis.

6 of upadacitinib in patients with rheumatoid arthritis.

7 infected, leading to severe and debilitating arthritis.

8 on and prevents joint damage in inflammatory arthritis.

9 int and gut inflammation during inflammatory arthritis.

10 isease progression in mice with inflammatory arthritis.

11 safety profiles, particularly in rheumatoid arthritis.

12 of bimekizumab as a treatment for psoriatic arthritis.

13 echanism during early stages of inflammatory arthritis.

14 zed by debilitating musculoskeletal pain and arthritis.

15 ly inflammatory bowel disease and rheumatoid arthritis.

16 recommended first-line agent for rheumatoid arthritis.

17 s including schistosomiasis, sarcoidosis and arthritis.

18 dylitis, and seronegative erosive rheumatoid arthritis.

19 s to confer a circadian signature to chronic arthritis.

20 t causes both acute and chronic debilitating arthritis.

21 of regulatory T cells and recovery from Lyme arthritis.

22 ntally different immunobiology to rheumatoid arthritis.

23 aged at least 18 years with active psoriatic arthritis.

24 ed light into the pathogenesis of autoimmune arthritis.

25 on of the sEH is a promising target to treat arthritis.

26 s a crucial function for bone erosion during arthritis.

27 c-9 was comparable to (18)F-FDG in detecting arthritis.

28 lammation and contribute to tissue damage in arthritis.

29 receptor agonist inhibits the development of arthritis.

30 hat VR23 can be selective against rheumatoid arthritis.

31 target in therapy of psoriasis and psoriatic arthritis.

32 ch as sepsis or systemic juvenile idiopathic arthritis.

33 can depict the inflamed synovial membrane in arthritis.

34 in the management of patients with psoriatic arthritis.

35 issue-protective actions during inflammatory arthritis.

36 e Janus kinase inhibitor to treat rheumatoid arthritis.

37 roidal anti-inflammatory drugs for psoriatic arthritis.

38 , 10 male) anti-TNF therapy for inflammatory arthritis.

39 ther strain, C57BL/6, develops minimal to no arthritis.

40 GM-CSF in autoantibody-mediated inflammatory arthritis.

41 , including spondyloarthritis and rheumatoid arthritis.

42 on of joint inflammation during inflammatory arthritis.

43 f psoriasis, Crohn's disease, and rheumatoid arthritis.

44 mine the ability of the new tracer to detect arthritis.

45 role of SAP in T1D and autoantibody-mediated arthritis.

46 sis of residual viral antigen-driven chronic arthritis.

47 nd safety for the management of inflammatory arthritis.

48 s inflammation and pathology in inflammatory arthritis.

49 own promoter of cancer growth, fibrosis, and arthritis.

50 tral event in the pathogenesis of rheumatoid arthritis.

51 ly events in the development of inflammatory arthritis.

52 tial novel therapeutic approach in psoriatic arthritis.

53 hose targeted in the treatment of rheumatoid arthritis.

54 ation, and mitigates experimental autoimmune arthritis.

55 e-dependent efficacy in rat collagen-induced arthritis.

56 effective and safe treatment of inflammatory arthritis.

57 ated the role of PON1 in murine inflammatory arthritis.

58 f people older than 60 years are affected by arthritis.

59 oint symptoms, which may evolve into chronic arthritis.

60 ls in 19 additional patients with rheumatoid arthritis.

61 rferi results in prolonged nonresolving Lyme arthritis.

62 he concerns of people living with rheumatoid arthritis?

63 common cause of secondary SS was rheumatoid arthritis (98.1%), followed by systemic lupus erythemato

64 and compared in vivo in an adjuvant-induced arthritis (AA) rat model in order to identify the ideal

65 activity correlated with lower BLM and lower arthritis activity in both K/BxN mice and RA patients.

66 Arthritis activity in K/BxN mice was associated with a m

67 tential of [(18)F]fluoro-PEG-folate to image arthritis activity in RA with favourable imaging charact

68 Non-invasive imaging of arthritis activity in rheumatoid arthritis (RA) patients

69 as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, giant cell arter

70 Rheumatoid arthritis affects individuals commonly during the most p

71 diabetes, cancer, neurological disorders and arthritis, among others, for >150 years, RGD has always

72 VTE risk is 4.7% in patients with rheumatoid arthritis and 2.5% in those without), and inherited thro

73 n used for decades to treat human rheumatoid arthritis and benefits from 70-y hindsight on medical us

74 inflammation in vivo during antigen-induced arthritis and experimental autoimmune encephalomyelitis,

75 tected in the synovial fluid from rheumatoid arthritis and gout patients.

76 a regulator of pathologic bone resorption in arthritis and highlight its potential as a target for fu

77 Mutations in FAMIN cause arthritis and inflammatory bowel disease in early childh

78 r human autoimmune disorders like rheumatoid arthritis and inflammatory bowel disease yet increases s

79 e the biodistribution, potential for imaging arthritis and kinetic properties of [18F]fluoro-PEG-fola

80 ase severity in mouse models of inflammatory arthritis and lung-graft rejection.

81 is a target for the treatment of rheumatoid arthritis and multiple sclerosis and is re-emerging as a

82 67269.FUNDINGNIAID and National Institute of Arthritis and Musculoskeletal and Skin Diseases of the N

83 Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases; the Nat

84 ty of musculoskeletal manifestations such as arthritis and non-inflammatory pain as well as with meta

85 Gout is the most common inflammatory arthritis and occurs when hyperuricaemia, sustained elev

86 rom pathological bone loss during rheumatoid arthritis and osteoporosis, whose pathogenesis is associ

87 inical outcomes for patients with rheumatoid arthritis and other chronic autoimmune diseases; however

88 line drug for the treatment of RA, psoriatic arthritis and other forms of inflammatory arthritis, and

89 use of belimumab in patients with rheumatoid arthritis and Sjogren's syndrome.

90 n rheumatoid arthritis, as well as psoriatic arthritis and spondyloarthritis, is bringing new insight

91 Systemic diagnosis with juvenile idiopathic arthritis and spondyloarthropathy were also associated w

92 s or older with active adult-onset psoriatic arthritis and symptoms for at least 6 months were random

93 asome activation contributes to inflammatory arthritis and systemic inflammation not only in RA, but

94 diseases such as atherosclerosis, rheumatoid arthritis and type 2 diabetes mellitus.

95 ar disease, 3 each on obesity and rheumatoid arthritis, and 2 on chronic kidney disease.

96 sh, and colitis, gastritis, pancreatitis and arthritis, and diabetic ketoacidosis each occurring in o

97 iated diseases, including SLE and rheumatoid arthritis, and following IgG Fcgamma receptor cross-link

98 ate-to-severe plaque psoriasis and psoriatic arthritis, and further agents are currently in clinical

99 re also performed in K/BxN mice with chronic arthritis, and in RA patients and healthy controls.

100 ic arthritis and other forms of inflammatory arthritis, and it enhances the effect of most biologic a

101 iency virus infection, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus predispose t

102 not suggest that patients with inflammatory arthritis are at increased risk of COVID-19.

103 Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision makin

104 ndent immune responses and passive models of arthritis are not affected by alcohol exposure.

105 CAI) agents for the management of rheumatoid arthritis are reported.

106 Using rheumatoid arthritis as an example of T cell mediated disease, we d

107 in larger group of patients with rheumatoid arthritis, as is planned for the next phase of clinical

108 ization of the synovial tissue in rheumatoid arthritis, as well as psoriatic arthritis and spondyloar

109 tic arthritis (PsA), reactive arthritis, the arthritis associated with inflammatory bowel disease inc

110 iologic-naive patients with active psoriatic arthritis (at least five swollen joints, at least five t

111 M-CSF signaling not only during inflammatory arthritis but also in experimental allergic encephalomye

112 familial linkage study of SLE and rheumatoid arthritis, but the association has not been explored fur

113 vels of asymptomatic hyperuricemia and gouty arthritis can ultimately clarify this issue.

114 number of comorbidities including psoriatic arthritis, cardiometabolic diseases, and depression.

115 orbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health d

116 Gout is a chronic arthritis caused by the deposition of poorly soluble mon

117 , BLT1(-/-) mice developed nonresolving Lyme arthritis characterized by increased neutrophils in the

118 uded: hypertension, coronary artery disease, arthritis, chronic kidney disease, heart failure, stroke

119 y common medical conditions (such as cancer, arthritis, chronic obstructive pulmonary disease (COPD),

120 plications including oncology and rheumatoid arthritis, could also be exploited in future DMD therapi

121 Whereas spontaneous arthritis depended on SAP in the autoantibody-mediated K

122 with numerous conditions such as rheumatoid arthritis, diabetes, systemic lupus erythematosus, infla

123 iologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, plac

124 c autoantibodies in patients with rheumatoid arthritis display a shift toward the pro-inflammatory Ig

125 k drives rhythmic repression of inflammatory arthritis during the night in mice, but mechanisms under

126 Arthralgia, arthritis, edema, and myalgia were more common in adults

127 that can affect peripheral and axial joints (arthritis), entheses, skin (psoriasis) and other structu

128 he in vivo efficacy of auranofin (rheumatoid arthritis FDA-approved drug) in a CDI mouse model and es

129 al profiles 1 to 2 weeks before a rheumatoid arthritis flare.

130 s a challenge for patients with inflammatory arthritis for several reasons, in particular, the safety

131 outcomes for many patients with inflammatory arthritis; for others, however, these agents do not subs

132 c drug (DMARD) treatment in the inflammatory arthritis groups (i.e. RA and UA) and confirmed by qRT-P

133 Many patients with psoriatic arthritis have an inadequate response to tumor necrosis

134 P-related diseases, such as cancer, but also arthritis, heart diseases, or pulmonary fibrosis.

135 ht/obesity and risk of developing rheumatoid arthritis, however, the evidence is not entirely consist

136 ndary panuveitis (HR = 4.21), and rheumatoid arthritis (HR = 3.30) were significantly associated with

137 subsequently develop persistent inflammatory arthritis (i.e. RA and UA) from those with NIA.

138 s such as carditis, neuritis, meningitis, or arthritis if not treated.

139 thy, and did not have diabetes or rheumatoid arthritis in 2000.

140 exacerbation of disease during inflammatory arthritis in a murine model.

141 significantly and safely improved psoriatic arthritis in a phase 2 study.

142 Arthritis in A20(ZF7) mice required T cells and MyD88, w

143 vivo, AdA treatment significantly alleviated arthritis in an LTB(4)-dependent murine arthritis model.

144 f arthritogenic K/BxN serum triggered robust arthritis in HoxB8 chimeras, but not in irradiated, nont

145 s overlaps with that of chronic inflammatory arthritis in joints.

146 tion of sPLA(2) promoted K/BxN serum-induced arthritis in mice, whereby ankle swelling was partially

147 to EAE, p40 also suppressed collagen-induced arthritis in mice.

148 The development of inflammatory arthritis in patients receiving immune checkpoint inhibi

149 hted imaging (DWI) was accurate in detecting arthritis in pediatric participants with juvenile idiopa

150 5% confidence intervals (CIs) for rheumatoid arthritis in relation to different measures of adiposity

151 c diseases, particularly skin infections and arthritis in severely immunocompromised patients.

152 ovium in osteoarthritis, the most widespread arthritis in the world, using the powerful tool of singl

153 experiences of pain among older adults with arthritis include the center of daily living, a lonely p

154 igger for some forms of chronic inflammatory arthritis, including spondyloarthritis and rheumatoid ar

155 recision medicine approaches in inflammatory arthritis, including strategies for predicting response

156 ased, dizziness, aphthous ulcer, arthralgia, arthritis, increased appetite, increased weight, restles

157 he Western Ontario and McMaster Universities Arthritis Index (WOMAC).

158 llagen antibody transfer (CAIA) was used for arthritis induction in B6 mice homozygous for the PON1 h

159 and baricitinib in patients with rheumatoid arthritis, inflammatory bowel diseases, psoriasis, or an

160 mouse model of antigen-induced inflammatory arthritis, intraarticular injection of Sdc3(-/-) MSCs yi

161 Rheumatoid arthritis is a chronic autoimmune disease that leads to

162 Arthritis is a common manifestation of systemic lupus er

163 The role of Siglec-15 in arthritis is still largely unclear.

164 iatric participants with juvenile idiopathic arthritis (JIA) or suspected of having JIA and showed ag

165 ment among patients with juvenile idiopathic arthritis (JIA)-associated uveitis treated with topical

166 rious rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset St

167 Rheumatoid arthritis, like many inflammatory diseases, is character

168 aneous development of debilitating psoriatic arthritis-like joint disease.

169 es MSC adhesion and efficacy in inflammatory arthritis, likely via induction of the AKT pathway.

170 s pathological conditions such as rheumatoid arthritis, liver fibrosis, or obesity.

171 thritis (RA) and other forms of inflammatory arthritis, low-dose methotrexate therapy remains the gol

172 ckade decreased inflammation in a rheumatoid arthritis model without reducing circulating autoantibod

173 vivo activity in a collagen antibody-induced arthritis model, where it showed biologic-like in vivo e

174 5 knockout mice and analyzed them in a mouse arthritis model.

175 ated arthritis in an LTB(4)-dependent murine arthritis model.

176 idin-4-yl) urea (TPPU) on a collagen-induced arthritis model.

177 triction improves outcome in multiple murine arthritis models and its removal induces preosteoclast m

178 mpelling data from in vitro and experimental arthritis models demonstrating its pro-inflammatory effe

179 vo, articular knockdown of miR-132 in murine arthritis models reduces the number of osteoclasts in th

180 nd unique CCL17-driven inflammatory pain and arthritis models, the latter permitting a radiation chim

181 Using a TNF-alpha-induced TMJ inflammatory arthritis mouse model, we found that the expression of N

182 pathogenesis of autoimmune diseases (such as arthritis, multiple sclerosis, psoriasis, inflammatory b

183 atory bowel disease (n = 27,739), rheumatoid arthritis (n = 25,324), systemic lupus erythematosus (n

184 disease (n = 8; 42%) and juvenile idiopathic arthritis (n = 6; 32%) were the commonest underlying con

185 Native joint septic arthritis (NJSA) is poorly studied.

186 In active rheumatoid arthritis, NOTCH3 and Notch target genes are markedly up

187 a debilitating immune-mediated inflammatory arthritis of unknown pathogenesis commonly affecting pat

188 y team determined the presence or absence of arthritis on the basis of clinical, laboratory, and imag

189 On day 14 after Y. enterocolitica infection (arthritis onset), we found that under TNFRp55 deficiency

190 tinal barrier integrity, effectively reduces arthritis onset.

191 ctive endocarditis, epidural abscess, septic arthritis, or osteomyelitis.

192 ients with acute Crohn's disease, rheumatoid arthritis, or sepsis were susceptible to both IgA- and I

193 ect older adults' experiences of living with arthritis pain across diverse ethnicities and cultures.

194 ' perceptions and experiences of living with arthritis pain can benefit healthcare experts in designi

195 patient-centered interventions for managing arthritis pain for older adults.

196 be sensitive to older adults' experience of arthritis pain, realize the importance of providers' sup

197 ore older adults' experiences of living with arthritis pain.

198 on older adults' experiences of living with arthritis pain; and (d) were published in English.

199 an emerging Alzheimer's disease, cancer, and arthritis pathogen and established agent of periodontiti

200 r 17 cell pathway is implicated in psoriatic arthritis pathogenesis.

201 leukocyte adhesion in the synovial fluids of arthritis patients and protect against sepsis.

202 ely, increased C3 expression by T cells from arthritis patients correlated with disease severity.

203 n the primary synovial cells from rheumatoid arthritis patients than those from healthy donors, sugge

204 ase-modifying antirheumatic drug-naive early arthritis patients, we assessed whether autocitrullinate

205 so has 15.97% prevalence in undifferentiated arthritis patients.

206 iscalimab in healthy subjects and rheumatoid arthritis patients.

207 ompassing conditions, such as low back pain, arthritis, persistent post-surgical pain, fibromyalgia,

208 1: A 52-year-old Thai female with rheumatoid arthritis presented with scleritis.

209 ) mice were infected with B. burgdorferi and arthritis progression was monitored by ankle swelling ov

210 Psoriatic arthritis (PsA) is a debilitating immune-mediated inflam

211 0% of the patients with PS develop psoriatic arthritis (PsA), a condition characterized by inflammato

212 or apremilast in psoriasis (PSOR), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) from 52

213 clude ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis, the arthritis assoc

214 uently used for the management of rheumatoid arthritis (RA) and other chronic conditions, but the saf

215 nsively in clinical management of rheumatoid arthritis (RA) and other chronic inflammatory diseases.

216 logic agents for the treatment of rheumatoid arthritis (RA) and other forms of inflammatory arthritis

217 d inflammatory diseases including rheumatoid arthritis (RA) and spondyloarthritis (SpA).

218 r treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

219 Patients with rheumatoid arthritis (RA) are at high risk of developing cardiovasc

220 hanisms of drug-free remission in rheumatoid arthritis (RA) are unknown.

221 rogressive debilitating nature of rheumatoid arthritis (RA) combined with its unknown etiology and in

222 ression signatures to distinguish rheumatoid arthritis (RA) from non-inflammatory arthralgia (NIA), s

223 Rheumatoid arthritis (RA) is a chronic immune-mediated disease that

224 Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune dise

225 Rheumatoid arthritis (RA) is a chronic inflammatory disease charact

226 Rheumatoid arthritis (RA) is a debilitating and painful inflammator

227 The primary manifestation of rheumatoid arthritis (RA) is articular disease; however, extra-arti

228 Rheumatoid arthritis (RA) is characterised by painful, stiff and sw

229 Rheumatoid arthritis (RA) is closely associated with shared epitope

230 rtant role in the pathogenesis of rheumatoid arthritis (RA) owing to their ability to generate citrul

231 imaging of arthritis activity in rheumatoid arthritis (RA) patients using macrophage PET holds promi

232 t C4d in pooled synovial fluid of rheumatoid arthritis (RA) patients.

233 Many patients with rheumatoid arthritis (RA) report symptom relief from certain foods.

234 Rheumatoid arthritis (RA) risk has a large genetic component (~60%)

235 The immunopathogenesis of rheumatoid arthritis (RA) spans decades, beginning with the product

236 one of the main cell types of the rheumatoid arthritis (RA) synovium, possess phenotypic and molecula

237 thy controls and 35 patients with rheumatoid arthritis (RA) were included.

238 Rheumatoid arthritis (RA), a chronic inflammatory disease affecting

239 of advances in the management of rheumatoid arthritis (RA), a substantial minority of patients are e

240 se (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), and others are increasingly recognized a

241 s critical to improve outcomes in rheumatoid arthritis (RA), but current diagnostic tools have limite

242 s in the hands is associated with rheumatoid arthritis (RA), it is unknown whether tenosynovitis of t

243 sociated with osteolysis, such as rheumatoid arthritis (RA), often leading to disability in patients.

244 inflamed joints of patients with rheumatoid arthritis (RA), together with compelling data from in vi

245 implicated in the pathogenesis of rheumatoid arthritis (RA), we evaluated the role of PON1 in murine

246 atient-derived in-vitro assay for Rheumatoid arthritis (RA), which yielded 5 promising genes, one of

247 utrophil extracellular trap (NET) rheumatoid arthritis (RA)-rmAbs derived from CD19(+) B cells within

248 drug primarily used for treating rheumatoid arthritis (RA).

249 tical role in the pathogenesis of rheumatoid arthritis (RA).

250 ta for classification accuracy of rheumatoid arthritis (RA).

251 sent in the sera of patients with rheumatoid arthritis (RA).

252 nt of autoimmune diseases such as rheumatoid arthritis (RA).

253 dicate immunological remission in rheumatoid arthritis (RA).

254 isk factor for the development of rheumatoid arthritis (RA).

255 tes disease in many patients with rheumatoid arthritis (RA).

256 affect type 1 diabetes (T1D) and rheumatoid arthritis (RA).

257 c inflammatory conditions such as rheumatoid arthritis (RA); however, it has only been during the twe

258 multiple sclerosis (MS, n = 147), rheumatoid arthritis (RA, n = 229), Crohn's disease (n = 148), or u

259 Yersinia enterocolitica O:3-induced reactive arthritis (ReA) in TNFRp55(-/-) mice.

260 tasis in a 48-year-old female with psoriatic arthritis, receiving methotrexate and infliximab.

261 ibitor baricitinib, used to treat rheumatoid arthritis, reduces inflammation by modifying the cytokin

262 ation modulator, in patients with rheumatoid arthritis refractory to biologic disease-modifying antir

263 In patients with rheumatoid arthritis refractory to biologic DMARDs, upadacitinib wa

264 Crohn's disease and ulcerative colitis, the arthritis related to anterior uveitis, and finally, some

265 o assess the effects these cells have on the arthritis-resistant phenotype characteristic of this mou

266 utrophils from the inflamed joint and failed arthritis resolution.

267 ce were associated with increased rheumatoid arthritis risk, suggesting adiposity could be targeted f

268 it binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety p

269 n children with systemic juvenile idiopathic arthritis (sJIA) and cytokine storm syndrome (CSS), a po

270 inflammatory arthralgia (NIA), self-limiting arthritis (SLA), and undifferentiated arthritis (UA) as

271 iographic outcome in patients with psoriatic arthritis, so that stratified medicine approaches can be

272 In patients with early inflammatory arthritis, ST6GALNAC1 is a potential biomarker for UA as

273 rus-mediated diseases do not induce clinical arthritis, suggesting that a local inflammatory niche de

274 presence of skin inflammation and the joint arthritis susceptibility in the host are only partially

275 viocytes tested ex vivo correlates with Lyme arthritis susceptibility.

276 ), a condition characterized by inflammatory arthritis that affects joints or entheses.

277 characterized by debilitating arthralgia and arthritis that can endure for months to years following

278 ng undergoes a major expansion in rheumatoid arthritis that is linked to disease activity(3-5); howev

279 In rheumatoid arthritis the synovial tissue undergoes marked hyperplas

280 is (AS), psoriatic arthritis (PsA), reactive arthritis, the arthritis associated with inflammatory bo

281 In rheumatoid arthritis, the target of the immune response is the syno

282 s in the blood from patients with rheumatoid arthritis; these cells shared features of inflammatory s

283 lection of blood in patients with rheumatoid arthritis to allow for longitudinal RNA sequencing (RNA-

284 be critical for enabling patients with hand arthritis to effectively use smartphone apps and might f

285 ns, including multiple sclerosis, rheumatoid arthritis, type-I diabetes, and cancer.

286 miting arthritis (SLA), and undifferentiated arthritis (UA) as compared to healthy controls as novel

287 joints of patients suffering from rheumatoid arthritis underwent a GM-CSF-independent necroptosis fol

288 f the intestinal barrier in the pre-phase of arthritis using butyrate or a cannabinoid type 1 recepto

289 inflammatory cell infiltrate, and persistent arthritis, via GM-CSF production, as deletion of NK cell

290 In addition, a patient with early rheumatoid arthritis was studied with both (68)Ga-DOTA-Siglec-9 and

291 With a focus on rheumatoid arthritis, we sought new insight into genetic mechanisms

292 /spine infections, osteomyelitis, and septic arthritis were labeled as IDRIs if discharge codes inclu

293 halangeal joints was specific for rheumatoid arthritis when compared with findings in patients with o

294 arthritis with features common to psoriatic arthritis, while mice expressing point mutations in A20'

295 sk profile in patients with active psoriatic arthritis who were naive to treatment with biologics.

296 A specific mouse strain, C3H/HeN develops arthritis with B. burgdorferi infection whereas another

297 itin-binding motif uniformly developed digit arthritis with features common to psoriatic arthritis, w

298 sgenic mouse develops spontaneous autoimmune arthritis with joint remodeling and profound bone loss.

299 r 52 weeks in patients with active psoriatic arthritis, with a musculoskeletal primary endpoint of Am

300 n (Western Ontario and McMaster Universities Arthritis [WOMAC] index); study type was randomized cont